Vitamin D compounds and myelodysplastic syndrome

Leukemia and Lymphoma

Volumn 49, Issue 1, 2008, Pages 12-13

  Okamoto, Ryoko ^a   Akagi, Tadayuki ^a   Koeffler, Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; ANTINEOPLASTIC AGENT; CALCITRIOL; CATHELICIDIN; COLECALCIFEROL; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEXAMETHASONE; DOXERCALCIFEROL; HYBRID PROTEIN; MYC PROTEIN; PARICALCITOL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISONE; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOID; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BACTERIAL INFECTION; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESEARCH; GENE CONTROL; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HUMAN; HYPERCALCEMIA; INHIBITION KINETICS; LEUKEMIA CELL; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NOTE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; RECEPTOR BINDING; TREATMENT DURATION; TREATMENT OUTCOME;

HUMANS; HYPERCALCEMIA; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME; VITAMIN D;

EID: 38549122802     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701757827     Document Type: Note

References (9)

1. Petrich, A., Kahl, B., Bailey, H., Kim, K., Turman, N. and Juckett, M. (2008) Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. Leuk Lymphoma, 49, pp. 57-61.
2. 3: In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep, 69, pp. 1399-1407.
3. 3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol, 38, pp. 67-68.
4. Mellibovsky, L., Díez, A., Pérez-Vila, E., Serrano, S., Nacher, M. and Aubía, J. (1998) Vitamin D treatment in myelodysplastic syndromes. Br J Haematol, 100, pp. 516-520.
5. Koeffler, H. P., Aslanian, N. and O'Kelly, J. (2005) Vitamin D (2) analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. Leuk Res, 11, pp. 1259-1262.
6. Molnar, I., Stark, N., Lovato, J., Powell, B. L., Cruz, J. and Hurd, D. D. (2007) Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000 - 4000 IU vitamin D(3)). Leukemia, 5, pp. 1089-1092.
7. Tiffany, N. M., Ryan, C. W., Garzotto, M., Wersinger, E. M. and Beer, T. M. (2005) High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: A phase I/II study. J Urol, 174, pp. 888-892.
8. 3. FASEB J, 19, pp. 1067-1077.
9. 3 is a direct inducer of antimicrobial peptide gene expression. J Immunol, 173, pp. 2909-2912.